Mizuho analyst Ann Hynes raised the firm’s price target on Charles River (CRL) to $174 from $155 and keeps a Neutral rating on the shares as part of a Q3 earnings preview for the healthcare facilities and managed care group. Healthcare utilization growth trends decelerated sequentially in Q3 despite easier year-over-year compares, which could indicate stabilizing cost trends, a positive for managed care companies, the analyst tells investors in a research note. The firm expects solid results from hospitals despite admissions trends falling sequentially. It is also “cautiously optimistic” that contract research organization trends have bottomed.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Strategic Divestiture and Value Unlocking: Charles River Labs’ Path to Growth
- Charles River, Toxys announce ReproTracker collaboration
- Charles River upgraded to Outperform from Market Perform at William Blair
- Charles River price target raised to $200 from $190 at Evercore ISI
- Nike upgraded, RH downgraded: Wall Street’s top analyst calls
